Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.43
NAS:SGYP's Cash to Debt is ranked lower than
51% of the 779 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. NAS:SGYP: 1.43 )
Ranked among companies with meaningful Cash to Debt only.
NAS:SGYP' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 1.43
F-Score: 3
Z-Score: -3.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -139.45
NAS:SGYP's ROA (%) is ranked lower than
98% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NAS:SGYP: -139.45 )
Ranked among companies with meaningful ROA (%) only.
NAS:SGYP' s ROA (%) Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -69.97
Current: -139.45
-6858.53
-69.97
ROC (Joel Greenblatt) (%) -21539.48
NAS:SGYP's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.31 vs. NAS:SGYP: -21539.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:SGYP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -423053.33  Med: -74545.45 Max: -666.67
Current: -21539.48
-423053.33
-666.67
EBITDA Growth (3Y)(%) 13.90
NAS:SGYP's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. NAS:SGYP: 13.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:SGYP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 29.2 Max: 131.7
Current: 13.9
0
131.7
EPS Growth (3Y)(%) 20.10
NAS:SGYP's EPS Growth (3Y)(%) is ranked higher than
69% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:SGYP: 20.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:SGYP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 29.1 Max: 122.4
Current: 20.1
0
122.4
GuruFocus has detected 2 Warning Signs with Synergy Pharmaceuticals Inc $NAS:SGYP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SGYP Guru Trades in Q4 2015

Jim Simons 397,600 sh (New)
Louis Moore Bacon 665,000 sh (+195.56%)
Steven Cohen 320,400 sh (+25.05%)
John Paulson 9,000,000 sh (unchged)
Paul Tudor Jones 22,074 sh (-48.07%)
» More
Q1 2016

SGYP Guru Trades in Q1 2016

Paul Tudor Jones 48,161 sh (+118.18%)
John Paulson 11,090,000 sh (+23.22%)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
» More
Q2 2016

SGYP Guru Trades in Q2 2016

John Paulson 27,756,668 sh (+150.29%)
Paul Tudor Jones 34,385 sh (-28.60%)
» More
Q3 2016

SGYP Guru Trades in Q3 2016

John Paulson 24,228,655 sh (-12.71%)
Paul Tudor Jones 18,144 sh (-47.23%)
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:SUPN, NAS:MNTA, OTCPK:KHTRF, NAS:DEPO, OTCPK:EVTCY, NAS:EGRX, NAS:IPXL, NYSE:DPLO, NAS:PCRX, OTCPK:GNMLF, OTCPK:TWMJF, OTCPK:NPPNY, NAS:AMPH, NYSE:LCI, NAS:ACET, NAS:SCMP, NAS:SCLN, NAS:FLXN, NAS:HRTX, NAS:RDUS » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals Inc is a biopharmaceutical company. It engages in the development of drugs to treat gastrointestinal, or GI, disorders and diseases.

Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.

Ratios

vs
industry
vs
history
P/B 93.18
SGYP's P/B is ranked lower than
99% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SGYP: 93.18 )
Ranked among companies with meaningful P/B only.
SGYP' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 102.52
Current: 93.18
0
102.52
EV-to-EBIT -8.38
SGYP's EV-to-EBIT is ranked lower than
99.99% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.56 vs. SGYP: -8.38 )
Ranked among companies with meaningful EV-to-EBIT only.
SGYP' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.17  Med: 0 Max: 0
Current: -8.38
-9.17
0
EV-to-EBITDA -8.40
SGYP's EV-to-EBITDA is ranked lower than
99.99% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.22 vs. SGYP: -8.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGYP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.19  Med: 0 Max: 0
Current: -8.4
-9.19
0
Current Ratio 4.71
SGYP's Current Ratio is ranked higher than
76% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. SGYP: 4.71 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.83 Max: 11.88
Current: 4.71
0.04
11.88
Quick Ratio 4.71
SGYP's Quick Ratio is ranked higher than
80% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. SGYP: 4.71 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.83 Max: 11.88
Current: 4.71
0.04
11.88

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.50
SGYP's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 429 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. SGYP: -19.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGYP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -248.4  Med: -21.2 Max: -14.6
Current: -19.5
-248.4
-14.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 128.20
SGYP's Price/Net Cash is ranked lower than
95% of the 211 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGYP: 128.20 )
Ranked among companies with meaningful Price/Net Cash only.
SGYP' s Price/Net Cash Range Over the Past 10 Years
Min: 4.63  Med: 22.61 Max: 582
Current: 128.2
4.63
582
Price/Net Current Asset Value 106.83
SGYP's Price/Net Current Asset Value is ranked lower than
97% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. SGYP: 106.83 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGYP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.48  Med: 16.22 Max: 301.5
Current: 106.83
4.48
301.5
Price/Tangible Book 91.57
SGYP's Price/Tangible Book is ranked lower than
99% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. SGYP: 91.57 )
Ranked among companies with meaningful Price/Tangible Book only.
SGYP' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.45  Med: 16.76 Max: 597.69
Current: 91.57
4.45
597.69
Earnings Yield (Greenblatt) (%) -11.97
SGYP's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SGYP: -11.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGYP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -36.2  Med: 0 Max: 0
Current: -11.97
-36.2
0

More Statistics

EPS (TTM) $ -1.22
Beta1.61
Short Percentage of Float17.61%
52-Week Range $2.50 - 6.97
Shares Outstanding (Mil)179.95

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 40 195 226
EPS ($) -1.07 -0.42 0.15 0.25
EPS w/o NRI ($) -1.07 -0.42 0.15 0.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:SGYP

Headlines

Articles On GuruFocus.com
John Paulson Trims Synergy Sep 23 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
Synergy Pharmaceuticals’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of... Jan 19 2017
Synergy wins U.S. approval for constipation drug Jan 19 2017
4:07 pm Synergy Pharma: FDA approves Trulance (plecanatide) for the treatment of Chronic Idiopathic... Jan 19 2017
Synergy Pharmaceuticals Inc (SGYP): A Top January Pick Ahead Of PDUFA Jan 17 2017
Key FDA Events to Watch Out for in Q1 Jan 17 2017
6 Major FDA Decisions and Biopharma Catalysts Coming in January and February Jan 06 2017
Coverage initiated on Synergy Pharma by Oppenheimer Jan 05 2017
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals... Jan 03 2017
Two Key FDA Decisions to Watch Out for in January 2017 Jan 02 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 30 2016
Synergy Pharmaceuticals Inc (SGYP) Moves Closer To Expanding Plecanatide Label Dec 30 2016
7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
SYNERGY PHARMACEUTICALS, INC. Financials Dec 28 2016
Synergy Reports Positive Top-Line Phase III Data on IBS Drug Dec 27 2016
Synergy Pharma rises after positive results Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)